BioCentury
ARTICLE | Company News

Recently launched Skyhawk raises $40M, announces Celgene partnership

June 29, 2018 2:52 PM UTC

Five months after its launch, spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.) raised $40 million in an equity investment and penned a deal with Celgene Corp. (NASDAQ:CELG) that includes a $60 million upfront payment.

New investors GreatPoint Ventures, ShangPharma, Celgene and undisclosed family investors participated in the equity investment, as did all major existing investors including Alexandria Venture Investments and the Duke of Bedford...